Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Epivir
Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-085841 · Präparat HOS-083204
6
In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of
cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also
support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of
lamivudine with cladribine is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage 1008a2ebb02e35b8202752fd12f0d4e850fec78e631202ae2dc37825c9a778a6 · Zeichen 1916–2295 im Abschnitt
Wechselwirkungen · Epivir
Epivir 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 22
HOS-085875 · Präparat HOS-083204
In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of
cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also
support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of
lamivudine with cladribine is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage 51ad00bfea94df2029f280ff74b7e4ad850ad9951817b4e89af95c0176e3afd3 · Zeichen 1922–2298 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) fluconazole (HOS-087945) phenobarbital (HOS-085617) phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660) cimetidine (HOS-085835) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-088517 · Präparat HOS-083663
8
efficacy in case of combination
in the clinical setting. Some
clinical findings also support a
possible interaction between
lamivudine and cladribine
OPIOIDS
Methadone/Lamivudine Interaction not studied. As only limited data are
Methadone/Zidovudine Zidovudine AUC 43% available the clinical
(30 to 90 mg once daily/200 mg Methadone AUC significance is not known.
every 4 hours) Monitor for signs of
zidovudine toxicity (see
section 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842) methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 14f192002bffc08afb0440dc52306b38bb35a6e271b9e54a60d13d4dfc570fac · Zeichen 7517–8430 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 100 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 7
HOS-089942 · Präparat HOS-083949
Cladribine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage fb6705205f39cb49dd945c2bd97dc43edd1e493e608ffcf2283dfd4c20a4efb0 · Zeichen 2117–2127 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 100 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 7
HOS-089943 · Präparat HOS-083949
In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of
cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also
support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of
lamivudine with cladribine is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 51ad00bfea94df2029f280ff74b7e4ad850ad9951817b4e89af95c0176e3afd3 · Zeichen 2129–2505 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.5 · PDF-Seite 22
HOS-089968 · Präparat HOS-083949
Cladribine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage fb6705205f39cb49dd945c2bd97dc43edd1e493e608ffcf2283dfd4c20a4efb0 · Zeichen 2116–2126 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.5 · PDF-Seite 22
HOS-089969 · Präparat HOS-083949
In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of
cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also
support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of
lamivudine with cladribine is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 51ad00bfea94df2029f280ff74b7e4ad850ad9951817b4e89af95c0176e3afd3 · Zeichen 2128–2504 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-108569 · Präparat HOS-093047
10
Drugs by Therapeutic Interaction Recommendation
Area Geometric mean change concerning co-
(%) administration
(Possible mechanism)
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied. Therefore, the concomitant
use of lamivudine with
In vitro lamivudine inhibits the cladribine is not
intracellular phosphorylation of recommended (see section
cladribine leading to a potential 4.4).
risk of cladribine loss of efficacy
in case of combination in the
clinical setting. Some clinical
findings also support a possible
interaction between lamivudine
and cladribine.
OPIOIDS
Methadone/Abacavir Abacavir: AUC As only limited data are
(40 to 90 mg once daily for 14 Cmax 35% available the clinical
days/600 mg single dose, then significance is not known.
600 mg twice daily for 14 Methadone: CL/F 22% Monitor for signs of
days) zidovudine toxicity (see
Methadone/Lamivudine Interaction not studied. section 4.8).
Methadone/Zidovudine Zidovudine AUC 43%
(30 to 90 mg once Methadone AUC Methadone dosage adjustment
daily/200 mg every 4 hours) unlikely in majority of
patients; occasionally
methadone re-titration may be
required.
RETINOIDS
Retinoid compounds Interaction not studied. Insufficient data to
(e.g. isotretinoin)/Abacavir recommend dosage
Possible interaction given adjustment.
common pathway of elimination
via alcohol dehydrogenase.
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Lamivudine
No drug interaction studies
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Zidovudine
URICOSURIC
Probenecid/Abacavir Interaction not studied. As only limited data are
Probenecid/Lamivudine Interaction not studied. available the clinical
Probenecid/Zidovudine Zidovudine AUC 106% significance is not known.
(500 mg four times Monitor for signs of
daily/2 mg/kg thrice daily) (UGT inhibition) zidovudine toxicity (see
section 4.8).
MISCELLANEOUS
Ethanol/Abacavir Abacavir: AUC 41% No dosage adjustment
(0.7 g/kg single dose/600 mg Ethanol: AUC necessary.
single dose)
(Inhibition of alcohol
dehydrogenase)
Ethanol/Lamivudine Interaction not studied.
Ethanol/Zidovudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842) methadone (HOS-086198) isotretinoin (HOS-108570) probenecid (HOS-085208) ethanol (HOS-089988)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 779b308db2f1cd8ed7b6c3456196c746580180c3977235a9bdd446b4f2a52234 · Zeichen 9177–13020 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-113481 · Präparat HOS-093937
Clinically significant interaction
unlikely. Cimetidine eliminated
only in part by renal organic
cation transport system.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied. Therefore, the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended (see
intracellular phosphorylation of section 4.4).
cladribine leading to a potential
risk of cladribine loss of
efficacy in case of combination
in the clinical setting. Some
clinical findings also support a
possible interaction between
lamivudine and cladribine
OPIOIDS
Methadone/Abacavir Abacavir: AUC No Kivexa dosage adjustment
(40 to 90 mg once daily for 14 Cmax 35% necessary.
days/600 mg single dose, then
600 mg twice daily for 14 days) Methadone: CL/F 22% Methadone dosage adjustment
unlikely in majority of
Methadone/Lamivudine Interaction not studied. patients; occasionally
methadone re-titration may be
required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) cimetidine (HOS-085835) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3bb42b8e96076847ca3aeb445cb6bf4f6cf7f1f0ef62e5fb0170f713aaf7d90c · Zeichen 6118–7873 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-129267 · Präparat HOS-096703
Clinically significant
interaction unlikely.
Cytotoxics
Cladribine/Lamivudine Interaction not studied. Concomitant use of Triumeq with
cladribine is not recommended (see
In vitro lamivudine section 4.4).
inhibits the intracellular
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage d348d7ff572e73d898dd06fa6b72ba9ca2c5cabdf00fd5ea5012bf4f82451eb5 · Zeichen 20238–20653 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-129269 · Präparat HOS-096703
12
phosphorylation of
cladribine leading to a
potential risk of cladribine
loss of efficacy in case of
combination in the
clinical setting. Some
clinical findings also
support a possible
interaction between
lamivudine and cladribine
Opioids
Methadone/Abacavir Abacavir: Methadone dose adjustment likely not
(40 to 90mg once daily for 14 AUC ↔ needed in majority of patients;
days/600mg single dose, then Cmax ↓35% occasionally methadone re-titration may
600mg twice daily for 14 days) be required.
Methadone:
CL/F ↑22%
Retinoids
Retinoid compounds Interaction not studied Insufficient data to recommend dose
(e.g. Isotretinoin) adjustment.
Possible interaction given
common pathway of
elimination via alcohol
dehydrogenase (abacavir-
component).
Miscellaneous
Alcohol
Ethanol/Dolutegravir Interaction not studied No dose adjustment necessary.
Ethanol/Lamivudine (Inhibition of alcohol
dehydrogenase)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842) methadone (HOS-086198) isotretinoin (HOS-108570) ethanol (HOS-089988)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage b1628c72c158b964dea3d515c6c762ac282af33315bd89f852898764f5f5550e · Zeichen 20703–22495 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-129360 · Präparat HOS-096703
Clinically significant
interaction unlikely.
Cytotoxics
Cladribine/Lamivudine Interaction not studied. Concomitant use of Triumeq with
cladribine is not recommended (see
In vitro lamivudine section 4.4).
inhibits the intracellular
phosphorylation of
cladribine leading to a
potential risk of cladribine
loss of efficacy in case of
combination in the
clinical setting. Some
clinical findings also
support a possible
interaction between
lamivudine and cladribine
Opioids
Methadone/Abacavir Abacavir: Methadone dose adjustment likely not
(40 to 90mg once daily for 14 AUC ↔ needed in majority of patients;
days/600mg single dose, then Cmax ↓35% occasionally methadone re-titration may
600mg twice daily for 14 days) be required.
Methadone:
CL/F ↑22%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cladribine (HOS-085842) methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 0a213fefbd7cf41fd6e551060e2d19e8bb1a9edffa1b2c1ac5838fd737843279 · Zeichen 16635–18090 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-142841 · Präparat HOS-098886
10
Cytotoxics
Cladribine/Lamivudine Interaction not studied. Concomitant use of Dovato with
cladribine is not recommended (see
In vitro lamivudine section 4.4).
inhibits the intracellular
phosphorylation of
cladribine leading to a
potential risk of cladribine
loss of efficacy in case of
combination in the
clinical setting. Some
clinical findings also
support a possible
interaction between
lamivudine and
cladribine.
Miscellaneous
Sorbitol
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine When possible, avoid chronic
13.4 g)/Lamivudine oral solution 300 mg. coadministration of Dovato with
medicinal products containing sorbitol
Lamivudine:
or other osmotic acting poly-alcohols or
AUC 14%; 32%; 36% monosaccharide alcohols (eg: xylitol,
mannitol, lactitol, maltitol). Consider
Cmax 28%; 52%, 55%.
more frequent monitoring of HIV-1 viral
load when chronic coadministration
cannot be avoided.
Potassium channel blockers
Fampridine (also known as Fampridine Co-administration of dolutegravir has
dalfampridine)/Dolutegravir the potential to cause seizures due to
increased fampridine plasma
concentration via inhibition of OCT2
transporter; co-administration has not
been studied. Fampridine co-
administration with Dovato is
contraindicated (see section 4.3).
Antacids and supplements
Magnesium/ Dolutegravir Magnesium/ aluminium-containing
aluminium-containing AUC 74% antacids should be taken well separated
antacids/Dolutegravir Cmax 72% in time from the administration of
Dovato (minimum 2 hours after or
(Complex binding to 6 hours before).
polyvalent ions)
Calcium Dolutegravir - When taken with food, Dovato and
supplements/Dolutegravir AUC 39% supplements or multivitamins containing
(fasted intake) Cmax 37% calcium, iron or magnesium can be taken
C24 39% at the same time.
(Complex binding to - If Dovato is taken in a fasted state,
polyvalent ions) such supplements should be taken a
Iron supplements/Dolutegravir Dolutegravir minimum 2 hours after or 6 hours before
(fasted intake) AUC 54% the intake of Dovato.
Cmax 57%
C24 56% The stated reductions in dolutegravir
(Complex binding to exposure were observed with the intake
polyvalent ions) of dolutegravir and these supplements
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): iron (HOS-085656) cladribine (HOS-085842) sorbitol (HOS-085845) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) maltitol (HOS-085849) potassium (HOS-086929) dalfampridine (HOS-124191) magnesium (HOS-085165) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 2518b802c4caa948477bdcec36197fbfdc295ad3c0b1c09f9b968f8a51fd6feb · Zeichen 18693–23302 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.